Intervention Review

You have free access to this content

Treatment of hypertension in peripheral arterial disease

  1. Deirdre A Lane,
  2. Gregory YH Lip*

Editorial Group: Cochrane Peripheral Vascular Diseases Group

Published Online: 4 DEC 2013

Assessed as up-to-date: 19 MAR 2013

DOI: 10.1002/14651858.CD003075.pub3


How to Cite

Lane DA, Lip GYH. Treatment of hypertension in peripheral arterial disease. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD003075. DOI: 10.1002/14651858.CD003075.pub3.

Author Information

  1. University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

*Gregory YH Lip, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham, B18 7QH, UK. g.y.h.lip@bham.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 4 DEC 2013

SEARCH

[Figure 1]
Figure 1. Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
[Figure 2]
Figure 2. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
[Figure 3]
Figure 3. Forest plot of comparison: 1 ACE inhibitors versus placebo, outcome: 1.1 Cardiovascular events.
[Figure 4]
Figure 4. Forest plot of comparison: 1 ACE inhibitors versus placebo, outcome: 1.3 Maximum walking distance.
[Figure 5]
Figure 5. Forest plot of comparison: 2 Calcium antagonists versus placebo, outcome: 2.1 Degree of diameter stenosis.
[Figure 6]
Figure 6. Forest plot of comparison: 2 Calcium antagonists versus placebo, outcome: 2.3 Arterial intima-media thickness.
[Analysis 1.1]
Analysis 1.1. Comparison 1 ACE inhibitors versus placebo, Outcome 1 Cardiovascular events.
[Analysis 1.2]
Analysis 1.2. Comparison 1 ACE inhibitors versus placebo, Outcome 2 Claudication distance.
[Analysis 1.3]
Analysis 1.3. Comparison 1 ACE inhibitors versus placebo, Outcome 3 Maximum walking distance.
[Analysis 1.4]
Analysis 1.4. Comparison 1 ACE inhibitors versus placebo, Outcome 4 Ankle brachial pressure index.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Calcium antagonists versus placebo, Outcome 1 Degree of diameter stenosis.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Calcium antagonists versus placebo, Outcome 2 Ankle brachial pressure index.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Calcium antagonists versus placebo, Outcome 3 Arterial intima-media thickness.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Thiazide diuretics versus alpha-adrenoreceptor blocking drugs, Outcome 1 Arterial intima-media thickness (IMT).
[Analysis 4.1]
Analysis 4.1. Comparison 4 Angiotensin-II receptor antagonist versus placebo, Outcome 1 Maximum walking distance at 12 months (m).
[Analysis 4.2]
Analysis 4.2. Comparison 4 Angiotensin-II receptor antagonist versus placebo, Outcome 2 Intima-media thickness at 12 months (cm).
[Analysis 4.3]
Analysis 4.3. Comparison 4 Angiotensin-II receptor antagonist versus placebo, Outcome 3 Ankle-brachial pressure index.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Beta-adrenoreceptor blockers versus thiazide diuretics, Outcome 1 Change in intermittent claudication distance.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Beta-adrenoreceptor blockers versus thiazide diuretics, Outcome 2 Absolute claudication distance.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Beta-adrenoreceptor blockers versus thiazide diuretics, Outcome 3 Change in ankle brachial pressure index.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Beta-adrenoreceptor blockers versus thiazide diuretics, Outcome 4 All-cause mortality.
[Analysis 5.5]
Analysis 5.5. Comparison 5 Beta-adrenoreceptor blockers versus thiazide diuretics, Outcome 5 Non-fatal cardiovascular events.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Beta-adrenoreceptor blockers versus beta-adrenoreceptor blockers, Outcome 1 All-cause mortality.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Beta-adrenoreceptor blockers versus beta-adrenoreceptor blockers, Outcome 2 Ankle brachial pressure index.
[Analysis 6.3]
Analysis 6.3. Comparison 6 Beta-adrenoreceptor blockers versus beta-adrenoreceptor blockers, Outcome 3 Intermittent claudication distance.
[Analysis 6.4]
Analysis 6.4. Comparison 6 Beta-adrenoreceptor blockers versus beta-adrenoreceptor blockers, Outcome 4 Absolute claudication distance.
[Analysis 6.5]
Analysis 6.5. Comparison 6 Beta-adrenoreceptor blockers versus beta-adrenoreceptor blockers, Outcome 5 Need for revascularisation.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Calcium antagonist-based strategy versus beta-adrenoreceptor blocker-based strategy, Outcome 1 Composite endpoint of death, non-fatal MI, or non-fatal stroke.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Calcium antagonist-based strategy versus beta-adrenoreceptor blocker-based strategy, Outcome 2 Composite endpoint of death, non-fatal MI or stroke, and revascularisation.